title: [Study of the prophylactic and therapeutic effect of human granulocyte-colony stimulating factor (G-CSF) on experimental pyelonephritis induced by pseudomonas aeruginosa in neutropenic mice].
abstract: We investigated the prophylactic and therapeutic effect of human granulocyte-colony stimulating factor (G-CSF) on mice with ascending pyelonephritis induced by Pseudomonas aeruginosa (G-group). This experimental model was established by a two course administration of cyclophosphamide, so that it kept the mice in a neutropenic status (around 2000 white blood cells/mm3) from the time of infection to the time of sacrifice. The cyclophosphamide-treated group increased their susceptibility more than the control group. In the cyclophosphamide-treated group, the prophylactic administration of G-CSF (2 micrograms/day/mouse) yielded a lower incidence of infection and of infection-induced mortality than that of saline alone. However, the therapeutic administration of G-CSF did not produce significant decreases of these rates, suggesting that this type of administration had no effect on infection. At the time of sacrifice, the prophylactic administration of G-CSF increased the number of neutrophils, while at the time of induced infection, no increase of neutrophils was found. G-CSF therapeutic administration was not able to increase neutrophils during the experiment. An investigation of the bacterial capacity of peritoneal exudate neutrophils revealed that G-CSF prophylactic administration accelerated its capacity, although cyclophosphamide alone did not. These results suggest that G-CSF has a prophylactic effect on bacterial infection in neutropenic mice, and that this effect, in part, depends upon both the increase of neutrophils and the acceleration of bactericidal capacity produced by G-CSF.
authors: N
authors: N
authors: Tanaka
authors: Y
authors: Y
authors: Kumamoto
authors: T
authors: T
authors: Hirose
authors: A
authors: A
authors: Yokoo
mesh_terms: D000380:Agranulocytosis / Q000150:complications*; D000818:Animals; D003115:Colony-Stimulating Factors / Q000627:therapeutic use*; D003520:Cyclophosphamide; D004198:Disease Susceptibility; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor; D006801:Humans; D007958:Leukocyte Count; D051379:Mice; D008815:Mice, Inbred Strains; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications*; D009504:Neutrophils / Q000276:immunology; D011552:Pseudomonas Infections / Q000517:prevention & control* / Q000628:therapy; D011704:Pyelonephritis / Q000517:prevention & control* / Q000628:therapy
chemical_list: D003115:Colony-Stimulating Factors; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide